Back to Interventions
Substance / Medication

Defibrotide

SNOMED 442263003UMLS C0057257

Overview

Active Ingredient
defibrotide
RxNorm CUI
1311089

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Veno-occlusive disease of the liver

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Recent Trials

Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide

NCT02876601Phase 4Completed20 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu Selim, Topaloglu Ozlem, Aggarwal Saurabh · Clin Drug Investig · 2022
PMID: 35594010Meta-AnalysisFull text (PMC)
Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Yang Liping, Qi Jiaqian, Pan Tingting et al. · Semin Thromb Hemost · 2019
PMID: 31627217Meta-Analysis
A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Hudspeth Michelle, Mori Shahram, Nachbaur David et al. · Haematologica · 2023
PMID: 36519326RCTFull text (PMC)
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.
Grupp Stephan A, Corbacioglu Selim, Kang Hyoung Jin et al. · Lancet Haematol · 2023
PMID: 37001534RCT
Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.
Richardson Paul G, Smith Angela R, Kernan Nancy A et al. · Transplant Cell Ther · 2021
PMID: 32950693RCTFull text (PMC)
Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers.
Schoergenhofer Christian, Buchtele Nina, Gelbenegger Georg et al. · Sci Rep · 2019
PMID: 31366975RCTFull text (PMC)
Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann Ursula, Fischer Joachim, Eber Stefan et al. · Haematologica · 2006
PMID: 16769582RCT
Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.
Ruggeri Annalisa, Corrado Francesco, Voza Antonio et al. · Haematologica · 2024
PMID: 38779740TrialFull text (PMC)
A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.
Jacobson Caron A, Rosenthal Allison C, Arnason Jon et al. · Blood Adv · 2023
PMID: 37399456TrialFull text (PMC)
Defibrotide Therapy for SARS-CoV-2 ARDS.
Frame David, Scappaticci Gianni B, Braun Thomas M et al. · Chest · 2022
PMID: 35413279TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Defibrotide (substance)
SNOMED CT
442263003
UMLS CUI
C0057257
RxNorm CUI
1311089

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.